The District of Columbia’s medical cannabis market saw steady growth in July 2025, with overall sales increasing by $405,345 compared to the previous month, according to The Alcoholic Beverage and Cannabis Administration monthly data. The gains were fueled almost entirely by manufacturers, while dispensaries continued to face stagnation despite the addition of new storefronts.
Manufacturing sales rose by $372,536, accounting for nearly all of July’s market growth. With more dispensaries entering the market, demand for wholesale products has surged, pushing manufacturer revenues up to nearly $2.63 million. Cultivation sales also showed modest growth, climbing from $753,271 to $783,403. By contrast, dispensary sales remained virtually flat despite the opening of five new medical dispensaries, bringing the citywide total to 55 operating locations.
The number of patients served jumped by more than 4,500 in July compared to June. D.C.-registered patients surged from 13,025 to 17,677, potentially reflecting a marketing push by new dispensaries eager to expand their customer base. However, sales tied to these local patients increased by less than $70,000, suggesting that many new patients are either making smaller purchases or not yet engaging heavily with the market. Meanwhile, the number of out-of-state temporary patients fell sharply—from 17,052 in June to 12,405 in July—after several months of steady growth.
Even with the decline, out-of-state patient sales continued to hover around half a million dollars, driven by a little over 2,000 buyers. The balance between local and non-resident participation remains a defining factor in D.C.’s cannabis market.
While the total number of operating dispensaries climbed to 55, average revenue per dispensary continued to decline, falling from $108,522 in June to $98,705 in July. The widening gap between patient registrations and dispensary sales highlights growing competition among retailers and may signal that the market is reaching a point of saturation.
Despite these challenges, the overall market continues to show robust year-over-year expansion. Total sales for July 2025 reached $8.84 million, nearly double the $4.49 million recorded in July 2024. Sales growth was broad-based, with increases reported across nearly every product category, including concentrates, flower, infused concentrates, pills, prerolls, tinctures, and vape cartridges.
As D.C.’s cannabis market matures, manufacturers remain the primary engine of growth, while dispensaries grapple with the challenges of rising competition and an increasingly complex patient landscape.
July in short
- Overall sales: Up $405,345 from June, reaching $8.84 million in July 2025.
- Year-over-year growth: Nearly doubled from $4.49 million in July 2024.
- Manufacturing sales: Rose $372,536, reaching almost $2.63 million.
- Cultivation sales: Increased slightly, from $753,271 to $783,403.
- Dispensary sales: Flat, despite five new dispensaries, bringing the total to 55.
- Average revenue per dispensary: Dropped from $108,522 to $98,705.
- Patients served: Increased by 4,500 from June.
- D.C. residents: Up from 13,025 to 17,677.
- Out-of-state patients: Fell from 17,052 to 12,405, but still contributed about $500,000 in sales.
- New D.C. patients’ sales impact: Less than $70,000 increase, suggesting limited purchasing activity.
- Product categories: Sales rose across concentrates, flower, infused concentrates, pills, prerolls, tinctures, and vape cartridges.
